Literature DB >> 23096132

The role of STAT3 activation in modulating the immune microenvironment of GBM.

Alfred P See1, James E Han, Jillian Phallen, Zev Binder, Gary Gallia, Fan Pan, Dilini Jinasena, Christopher Jackson, Zineb Belcaid, Sung Jin Jeong, Chelsea Gottschalk, Jing Zeng, Jacob Ruzevick, Sarah Nicholas, Young Kim, Emilia Albesiano, Drew M Pardoll, Michael Lim.   

Abstract

Glioblastoma multiforme (GBM) modulates the immune system to engance its malignant potential. Signal transducer and activator of transcription 3 (STAT3) activation is a regulatory node in modulating the immune microenvironment in several human tumors, including GBM. To investigate whether STAT3 inhibition might enhance anti-tumor responses, we inhibited STAT3 signaling using small interfering RNA against STAT3. We tested the human GBM cell lines U87, U251, and HS683, which are known to constitutively express high levels of phospho-STAT3. STAT3 inhibition resulted in enhanced expression of several pro-inflammatory cytokines and chemokines and supernatants from STAT3-silenced human GBM cell lines increased lipopolysaccharide-induced dendritic cell activation in vitro. We obtained comparable results when STAT3 activity was suppressed with specific small molecule inhibitors. Our results support the hypothesis that activated STAT3 contributes to the immunosuppressive microenvironment in GBM and support previous studies implicating STAT3 as a potential target for immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23096132      PMCID: PMC3700337          DOI: 10.1007/s11060-012-0981-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  43 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Selective expansion of foxp3-positive regulatory T cells and immunosuppression by suppressors of cytokine signaling 3-deficient dendritic cells.

Authors:  Yumiko Matsumura; Takashi Kobayashi; Kenji Ichiyama; Ryoko Yoshida; Masayuki Hashimoto; Tomohito Takimoto; Kentaro Tanaka; Takatoshi Chinen; Takashi Shichita; Tony Wyss-Coray; Katsuaki Sato; Akihiko Yoshimura
Journal:  J Immunol       Date:  2007-08-15       Impact factor: 5.422

3.  Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain.

Authors:  David Zagzag; Konstantin Salnikow; Luis Chiriboga; Herman Yee; Li Lan; M Aktar Ali; Roberto Garcia; Sandra Demaria; Elizabeth W Newcomb
Journal:  Lab Invest       Date:  2005-03       Impact factor: 5.662

4.  Signal transducer and activator of transcription-3 and breast cancer prognosis.

Authors:  Takahiro Sato; Lynn Moretti Neilson; Amy R Peck; Chengbao Liu; Thai H Tran; Agnes Witkiewicz; Terry Hyslop; Marja T Nevalainen; Guido Sauter; Hallgeir Rui
Journal:  Am J Cancer Res       Date:  2011       Impact factor: 6.166

5.  Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment.

Authors:  Linda M Liau; Robert M Prins; Sylvia M Kiertscher; Sylvia K Odesa; Thomas J Kremen; Adrian J Giovannone; Jia-Wei Lin; Dennis J Chute; Paul S Mischel; Timothy F Cloughesy; Michael D Roth
Journal:  Clin Cancer Res       Date:  2005-08-01       Impact factor: 12.531

6.  Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma.

Authors:  Yasuharu Akasaki; Gentao Liu; Nancy H C Chung; Moneeb Ehtesham; Keith L Black; John S Yu
Journal:  J Immunol       Date:  2004-10-01       Impact factor: 5.422

Review 7.  STATs in cancer inflammation and immunity: a leading role for STAT3.

Authors:  Hua Yu; Drew Pardoll; Richard Jove
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

8.  Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors.

Authors:  Joannes F M Jacobs; Albert J Idema; Kalijn F Bol; Stefan Nierkens; Oliver M Grauer; Pieter Wesseling; J André Grotenhuis; Peter M Hoogerbrugge; I Jolanda M de Vries; Gosse J Adema
Journal:  Neuro Oncol       Date:  2008-11-21       Impact factor: 12.300

9.  Initiation of immune responses in brain is promoted by local dendritic cells.

Authors:  Jozsef Karman; Changying Ling; Matyas Sandor; Zsuzsanna Fabry
Journal:  J Immunol       Date:  2004-08-15       Impact factor: 5.422

10.  Adenovirus-mediated delivery of bFGF small interfering RNA reduces STAT3 phosphorylation and induces the depolarization of mitochondria and apoptosis in glioma cells U251.

Authors:  Jun Liu; Xinnv Xu; Xuequan Feng; Biao Zhang; Jinhuan Wang
Journal:  J Exp Clin Cancer Res       Date:  2011-09-09
View more
  26 in total

1.  Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas.

Authors:  Jennifer E Kim; Mira A Patel; Antonella Mangraviti; Eileen S Kim; Debebe Theodros; Esteban Velarde; Ann Liu; Eric W Sankey; Ada Tam; Haiying Xu; Dimitrios Mathios; Christopher M Jackson; Sarah Harris-Bookman; Tomas Garzon-Muvdi; Mary Sheu; Allison M Martin; Betty M Tyler; Phuoc T Tran; Xiaobu Ye; Alessandro Olivi; Janis M Taube; Peter C Burger; Charles G Drake; Henry Brem; Drew M Pardoll; Michael Lim
Journal:  Clin Cancer Res       Date:  2016-06-29       Impact factor: 12.531

Review 2.  EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy.

Authors:  Cristina Zahonero; Pilar Sánchez-Gómez
Journal:  Cell Mol Life Sci       Date:  2014-03-27       Impact factor: 9.261

Review 3.  The role of STAT3 in tumor-mediated immune suppression.

Authors:  Sherise D Ferguson; Visish M Srinivasan; Amy B Heimberger
Journal:  J Neurooncol       Date:  2015-02-22       Impact factor: 4.130

Review 4.  Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies.

Authors:  Joanna Y Wang; Chetan Bettegowda
Journal:  J Neurooncol       Date:  2015-02-21       Impact factor: 4.130

5.  Stat3-positive tumor cells contribute to vessels neoformation in primary central nervous system lymphoma.

Authors:  Simona Ruggieri; Roberto Tamma; Nicoletta Resta; Francesco Albano; Nicoletta Coccaro; Daria Loconte; Tiziana Annese; Mariella Errede; Giorgina Specchia; Rebecca Senetta; Paola Cassoni; Domenico Ribatti; Beatrice Nico
Journal:  Oncotarget       Date:  2017-05-09

6.  E804 induces growth arrest, differentiation and apoptosis of glioblastoma cells by blocking Stat3 signaling.

Authors:  Yanmin Zhang; Zhaoxiao Du; Zirong Zhuang; Yanjun Wang; Fen Wang; Shuai Liu; Han Wang; Hairong Feng; Haoyuan Li; Liyan Wang; Xianghong Zhang; Aijun Hao
Journal:  J Neurooncol       Date:  2015-09-19       Impact factor: 4.130

Review 7.  Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.

Authors:  Zangbéwendé Guy Ouédraogo; Julian Biau; Jean-Louis Kemeny; Laurent Morel; Pierre Verrelle; Emmanuel Chautard
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

8.  The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction.

Authors:  Benjamin T Himes; Timothy E Peterson; Tristan de Mooij; Luz M Cumba Garcia; Mi-Yeon Jung; Sarah Uhm; David Yan; Jasmine Tyson; Helen J Jin-Lee; Daniel Parney; Yasmina Abukhadra; Michael P Gustafson; Allan B Dietz; Aaron J Johnson; Haidong Dong; Rachel L Maus; Svetomir Markovic; Fabrice Lucien; Ian F Parney
Journal:  Neuro Oncol       Date:  2020-07-07       Impact factor: 12.300

Review 9.  Insights in the immunobiology of glioblastoma.

Authors:  Dimitrios Strepkos; Mariam Markouli; Alexia Klonou; Christina Piperi; Athanasios G Papavassiliou
Journal:  J Mol Med (Berl)       Date:  2019-10-24       Impact factor: 4.599

10.  Myeloid STAT3 promotes formation of colitis-associated colorectal cancer in mice.

Authors:  Paulina Pathria; Dagmar Gotthardt; Michaela Prchal-Murphy; Eva-Maria Putz; Martin Holcmann; Michaela Schlederer; Beatrice Grabner; Ilija Crncec; Jasmin Svinka; Monica Musteanu; Thomas Hoffmann; Martin Filipits; Walter Berger; Valeria Poli; Lukas Kenner; Martin Bilban; Emilio Casanova; Mathias Müller; Birgit Strobl; Editha Bayer; Thomas Mohr; Veronika Sexl; Robert Eferl
Journal:  Oncoimmunology       Date:  2015-01-22       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.